Background: Percutaneous coronary intervention (PCI) with new-generation drug-eluting stents is increasingly performed in elderly patients, who generally have more comorbidities and more technically challenging target lesions. Nevertheless, there is a paucity of reported data on the long-term safety and efficacy of PCI with contemporary stents in elderly all-comers.
Methods: This prespecified secondary analysis of a large-scale randomized clinical trial (BIONYX; clinicaltrials.gov:NCT02508714) compared in elderly all-comers (≥ 75 years) the 5-year outcome after PCI with the novel, more radiopaque Onyx zotarolimus-eluting stent (ZES) versus the Orsiro sirolimus-eluting stent (SES). We assessed the main composite endpoint target vessel failure (TVF: cardiac death, target vessel myocardial infarction, or target vessel revascularization) and several secondary endpoints.
Results: Of 2,488 trial participants, 475(19.1%) were elderly (79.5 ± 3.5 years), including 165(34.7%) women. There was a significant between-stent difference in the main endpoint TVF in favor of the Onyx ZES (14.4% vs. 24.2%, HR: 0.60, 95% CI 0.39-0.93, p = 0.02). The time-to-event curves displayed between-stent dissimilarities across all components of TVF, yet not statistically significant. Landmark analysis between 1- and 5-year follow-up showed in Onyx ZES-treated patients significantly lower rates of TVF (7.8% vs.8.9%, p = 0.002) and target vessel revascularization (3.0% vs.8.3%, p = 0.029). In addition, the 5-year rates of all-cause mortality and several composite endpoints were lower (p < 0.03) in Onyx ZES-treated patients.
Conclusions: In elderly all-comer patients, those treated with Onyx ZES showed a lower 5-year incidence of the main endpoint of safety and efficacy, as well as several secondary endpoints, than patients treated with Orsiro SES. Further research on this issue is warranted.
Clinical Trial Registration Information: https://clinicaltrials.gov/study/NCT02508714.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1007/s00392-025-02622-7 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Bleeding management in pelvic trauma: state of the art.
Curr Opin Anaesthesiol
February 2025
Department of Orthopaedics and Trauma Surgery.
Purpose Of Review: Bleeding complications from pelvic injuries occur after high-energy trauma as well as after low-energy trauma in elderly patients and are the main contributors to mortality. Demographic changes necessitate focussing on both entities and targeted therapies throughout the course of management.
Recent Findings: This article reviews the recent evidence and expertise on bleeding management for haemodynamically unstable patients with pelvic fractures with insights from prehospital care to trends in resuscitation and endovascular techniques and revival of older strategies, to challenges of definitive treatment.
Macromolecular Crowding Supports the Generation of Basal Membrane-Rich Pericyte-Based Cell Sheets Useful for Cell Therapy of Diabetic Wounds.
Cell Transplant
March 2025
Cardiovascular Research Unit, IRCCS MultiMedica, Milan, Italy.
Diabetic foot ulcers (DFUs) are associated with a high risk of amputations and a 50% 5-year survival rate due at least in part to the limited angiogenic and wound healing capacity of patients with diabetes. Cell therapy via intramuscular injection of peripheral blood mononuclear cells showed encouraging but limited results. Such limitations may arise from the limited ability of therapeutic cells to adhere to the target tissue.
View Article and Find Full Text PDFEmerging PET radiotracers for vascular imaging.
Rheumatology (Oxford)
March 2025
Section of Cardiorespiratory Medicine, Victor Phillip Dahdaleh Heart and Lung Research Institute, University of Cambridge, Cambridge, UK.
Imaging plays an important role in the clinical management of patients with large-vessel vasculitis (LVV), both to confirm the diagnosis at the time of initial presentation and to identify disease relapses in individuals with established disease. The big advantage of PET imaging over other non-invasive imaging modalities is the ability to employ targeted radionuclide probes to localize and track cellular pathways, providing in vivo assessments of disease activity. While 18F-fluorodeoxyglucose (FDG) has good diagnostic accuracy for LVV, this tracer is taken up by all glucose metabolizing cells in the vessel wall and so non-specific arterial uptake that is often unrelated to inflammatory disease activity can occur in patients despite a good clinical response to treatment.
View Article and Find Full Text PDFEmerging cell therapies in the vasculitis field.
Rheumatology (Oxford)
March 2025
Department of Pathology and Laboratory Medicine, University of North Carolina at Chapel Hill, Chapel Hill, NC, USA.
ANCA vasculitis is a systemic autoimmune small-vessel vasculitis characterized by autoantibodies targeting either MPO or PR3. While patients with ANCA vasculitis are successfully treated with broad-spectrum immunosuppression, these treatments often leave patients vulnerable to infections. Research in the field has made positive gains in regards to understanding autoantigen specificity and immune cell subset involvement in disease pathogenesis, relapse and remission.
View Article and Find Full Text PDFAspirin-triggered DHA metabolites inhibit angiogenesis.
Front Pharmacol
February 2025
Department of Pharmaceutical and Pharmacological Sciences, University of Padova, Padova, Italy.
Background And Aim: Blood vessels supply oxygen, nutrients and provide gateways for immune surveillance. Since this network nourishes all tissues, vessel abnormalities contribute to many diseases, such as cancer. One of the potential targets for Docosahexaenoic Acid (DHA) in cancer is suppressing angiogenesis, a process of new blood vessel formation within tumors.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!